To review the potential association between Chlamydia pneumoniae (CP) infection and coronary artery disease (CAD), and to describe possible therapeutic interventions.
DATA SOURCES:
A MEDLINE search of literature (January 1966– January 1998) pertaining to CP infection associated with heart disease was performed. Additional literature was obtained from review of journals and reference lists of pertinent articles identified through the search.
STUDY SELECTION AND DATA EXTRACTION:
All articles involving CP and CAD were considered for possible inclusion in this review. Other selected articles involved possible links between infection and the atherosclerotic process, inflammation and inflammatory mediators in the atherosclerotic process, and isolation of CP from human tissue.
DATA SYNTHESIS:
Numerous reports have suggested an association between chronic CP and CAD. CP has been seroepidemiologically linked to CAD. The organism has also been isolated from atherosclerotic lesions. Two reports in humans and one report in animals have shown that macrolide therapy (azithromycin or roxithromycin) may decrease the risk of adverse cardiovascular events.
CONCLUSIONS:
Evidence seems to support an association between CP infection and an increased incidence of CAD. Additional and larger seroepidemiologic studies of this association need to be performed to establish a causal relationship between infection and CAD. Determination of the actual role of CP in CAD may decide the role of specific antichlamydial therapy in the management of this condition.
ThomDHGraystonJTSiscovickDSWangSPWeissNSDalingJR. Association of prior infection with Chlamydia pneumoniae and angio-graphically demonstrated coronary artery disease. JAMA1992;268: 68–72.
3.
OslerW. Diseases of the arteries. In: OslerW, ed. Modern medicine: its practice and theory. Philadelphia: Lea and Febiger, 1908: 429–47.
4.
BurchGEHarbJMHiramotoYSheweyL. Viral infection of the aorta of man associated with early atherosclerotic changes. Am Heart J1973;86: 523–34.
5.
NichollsACThomasM. Coxsackie virus infection in acute myocardial infarction. Lancet1977;1: 883–4.
6.
GrattanMTMoreno-CabralCEStarnesVAOyerPEStinsonEBShumwayNE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA1989;261: 3561–6.
7.
LowryRWAdamEHuCKleimanNSCocanougherBWindsorTWhat are the implications of cardiac infection with cytomegalovirus before heart transplantation?J Heart Lung Transplant1994;13:122–8.
8.
BendittEPBarrettTMcDougallJK. Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A1983;80: 6386–9.
9.
GyorkeyFMelnickJLGuinnGAGyorkeyPDeBakeyME. Herpesviridae in the endothelial and smooth muscle cells of the proximal aorta in arteriosclerotic patients. Exp Mol Pathol1984;40: 328–31.
10.
MatillaKJValleMSNieminenMSValtonenVVHietaniemiKL. Dental infections and coronary atherosclerosis. Atherosclerosis1993;103: 205–11.
11.
PatelPMendallMACarringtonDStrachanDPLeathamEMolineauxNAssociation of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ1995;311:711–4.
12.
MendallMAGogginPMMolineauxNLevyJToosyTStrachanDRelation of Helicobacter pylori infection and coronary heart disease. Br Heart J1994;71:437–9.
13.
SaikkuPLeinonenMTenkanenLLinnanmakiEEkmanMRManninenVChronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med1992;116:273–8.
14.
SaikkuP. Chlamydia pneumoniae infection as a risk factor in acute myocardial infarction. Eur Heart J1993;14 (suppl): 62–5.
KuoCCShorACampbellLAFukushiAPattonDLGraystonJT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis1993;167: 841–9.
17.
WangSPGraystonJT. Population prevalence of antibody to Chlamydia pneumoniae strain TWAR. In: BowieWRStammWEWardMERidgwayGLSchachterJCaldwellHD, eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990: 402–5.
18.
BiermanEL. Atherosclerosis and other forms of arteriosclerosis. In: IsselbacherKJBraunwaldEWilsonJDMartinJBFauciASKasperDL, eds. Harrison's principles of internal medicine. New York: McGraw-Hill, 1994: 1106–16.
19.
RossR. The pathogenesis of atherosclerosis: An update. N Engl J Med1986;314: 488–500.
20.
FernandopulleRLoscalzoJ. Atherosclerosis. In: LillyLS, ed. Pathophysiology of heart disease. Philadelphia: Lea and Febiger, 1993: 84–97.
21.
BetzholtzCJohnsonAHeldenCHWestermarkBLindPUrdeaMSC-DNA and chromosomal localization of human platelet derived growth factor A-gene and its expression in tumor cell lines. Nature1986;320:695–9.
22.
MinickCRFabricantCGFabricantJLitrenaMM. Atherosclerosis induced by infection with a herpes virus. Am J Pathol1979;96: 673–706.
23.
HajjarDPPomerantzKBFalconeDJWekslerBBGrantAJ. Herpes simplex virus infection in human arterial cells: Implications in atherosclerosis. J Clin Invest1987;80: 1317–21.
24.
BevilacquaMPPoberJSMajeauGRFiersWCotranRSGombroneMAJr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization and comparison with the actions of interleukin-1. Proc Natl Acad Sci U S A1986;83: 4533–7.
25.
VallancePCollierJBhagatK. Infection, inflammation and infarction: Does acute endothelial cell dysfunction provide a link? Lancet1997;349: 1391–2.
26.
MehtaJLSaldeenTGRandK. Interactive role of infection, inflammation, and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol1998;31: 1217–25.
HahnDL. Regional variation in ischemic heart disease: A possible missing risk factor? J Clin Epidemiol1993;46: 668–9.
31.
EllisRW. Infection and coronary heart disease. J Med Microbiol1997;46: 535–9.
32.
LiuzzoGBiasucciLMGallimoreJRGrilloRLRebuzziAGPepysMBThe prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med1994;331:417–24.
33.
MendallMAPatelPBallamLStrachanDNorthfieldTC. C-reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study. BMJ1996;312: 1061–5.
34.
PatelPCarringtonDStrachanDPLeathamEGogginPNorthfieldTCFibrinogen: A link between chronic infection and coronary heart disease. Lancet1994;343:1634–5.
35.
FowkesFGRLoweGDOHouseleyERattrayARumleyAEltonRACross-linked fibrin degradation products, progression of peripheral arterial disease and risk of coronary heart disease. Lancet1993;342:84–6.
36.
TewariABuhlesWCStarnesHF. Preliminary report: Effects of interleukin-1 in platelet counts. Lancet1990;936: 712–4.
37.
RitchyDGLevyBAAdamsMAFullerGM. Regulation of fibrinogen synthesis by plasma-derived fragments of fibrinogen and fibrin: An indirect feedback pathway. Proc Natl Acad Sci U S A1982;79: 1530–4.
38.
Van LentenBJFogerlmanAMHaberlandMEEdwardsPA. The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A1986;83: 2704–8.
39.
Lopes-VirellMF. Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J1994;14 (suppl K): 118–24.
40.
GambleJRHarlanJMKlebanoffSJVadasMA. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumour necrosis factor. Proc Natl Acad Sci U S A1985;82: 8667–71.
41.
MiettinenHLehtoSSaikkuPHaffnerSMRonnemaaTPyoralaK. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetics and nondiabetic subjects in Finland. Eur Heart J1996;17: 682–8.
42.
OssewaardeJMVallingaCFeskensEJMKromhoutD. Infection with Chlamydia pneumoniae as a risk factor for coronary heart disease (the Zuthpen elderly study) (abstract). Atherosclerosis1995;115 (suppl):41.
43.
MelnickSLShaharEFolsomARGraystonJTSorliePDWangSPPast infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis. Am J Med1993;95:499–504.
44.
SaikkuPLeinonenMMattilaKEkmanMRNieminenMSMakelaPHSerological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet1988;2:983–6.
45.
LinnanmakiELeinonenMMattilaKNieminenMSValtonenVSaikkuP. Chlamydia pneumoniae—specific circulating immune complexes in patients with chronic coronary heart disease. Circulation1993;87: 1130–4.
46.
RamirezJAAhkeeSSummersgillJTGanzelBLOgdenLLQuinnTCIsolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med1996;125:979–82.
47.
MendallMACarringtonDStrachanDPatelPMolineauxNLeviJChlamydia pneumoniae: Risk factors for seropositivity and association with coronary heart disease. J Infect1995;30:121–8.
48.
WeissSMRoblinPMGaydosCACummingsPPattonDLSchulhoffNFailure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy. J Infect Dis1996;173:957–62.
49.
AcetiAMazzacuratiGAmendoleaMAPennicaAZechiniBTrappoliniM. H. pylori and C. pneumoniae infections may account for most acute coronary syndromes. BMJ1996;313: 428–9.
50.
JuvonenJLaurilaAJuvonenTAlakarppaHSurcelHMLounatmaaKDetection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol1997;29:1054–9.
51.
MuhlesteinJBHammondEHCarlquistJFRadickeEThompsonMJKaragounisLAIncreased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerosis versus other forms of cardiovascular disease. J Am Coll Cardiol1996;27:1555–61.
52.
JacksonLACampbellLASchmidtRAKuoCCCappuccioALLeeMJSpecificity of detection of Chlamydia pneumoniae in cardiovascular atheroma: Evaluation of the innocent bystander hypothesis. Am J Pathol1997;150:1785–90.
53.
DahlenDHBomanJBirganderLSLindblomB. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis1995;114: 165–74.
54.
CookPJLipGYHWiseR. Chlamydia pneumoniae and acute arterial thrombotic disease. Circulation1995;92: 3148–9.
55.
MaasMBartelsCEngelPMamatUSieversHH. Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol1998;31: 827–32.
56.
GranforsK. Measurement of immunoglobulin M (IgM), IgG and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunoabsorbent assay: Persistence of serum antibodies during disease. J Clin Microbiol1979;9: 336–41.
57.
HoibyNDoringG. Immunoglobulin responses and immune complex formation in chronic lung diseases. Clin Microbiol News1988;9: 133–6.
58.
BrettMMGhoneimATLittlewoodJM. Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis. Arch Dis Child1990;65: 259–63.
59.
SarovISarovBLunefeldEHagaiZChaimWFiguraB. The significance of Chlamydia-specific serum IgA antibodies in Chlamydia trachomatis infections. First Proceedings of the European Society of Chlamydia Research. Stockholm: Almqvist and Wiksell Int., 1988: 234–8.
60.
ChaimWSarovBSarovIPiuraBCohenAInslerV. Serum IgG and IgA antibodies to Chlamydia in ectopic pregnancies. Contraception1989;40: 59–71.
61.
PatnodeDWangSPGraystonJ. Persistence of Chlamydia pneumoniae, strain TWAR microimmunofluorescent antibody. In: BowieWRStammWEWardMERidgwayGLSchachterJCaldwellHD, eds. Chlamydial infections. Cambridge: Cambridge University Press, 1990: 406–9.
62.
AndersonPPedersonOFBachBBondeGL. Serum antibodies and immunoglobulins in smokers and nonsmokers. Clin Exp Immunol1982;47: 467–73.
63.
MiliFFlandersWDBoringJRAnnestJLDestefanoF. The associations of race, cigarette smoking and smoking cessation to measures of the immune system in middle-aged men. Clin Immunol Immunopath1991;59: 187–200.
64.
BlakeGHAbellTStanleyW. Cigarette smoking and upper respiratory tract infection among recruits in basic combat training. Ann Intern Med1988;109: 198–202.
65.
KarvonenMTuomilehtoJPitkaniemiJNaukkarinenASaikkuP. Importance of smoking for Chlamydia pneumoniae seropositivity. Int J Epidemiol1994;23: 1315–21.
66.
HahnDLSaikkuP. Chlamydia, smoking and heart disease (letter). Ann Intern Med1992;117:71.
67.
LeinonenM. Pathogenetic mechanisms and epidemiology of Chlamydia pneumoniae. Eur Heart J1993;14:(suppl K): 57–61.
68.
GaydosCASummersgillJTSahneyNNRamirezJAQuinnTC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun1996;64: 1614–20.
69.
MuhlesteinJBAndersonJLHammondEHZhaoLTrehanSSchwobeEPInfection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation1998;97:633–6.
70.
GurfinkelEBozovichGDarocaABeckEMautnerB. Randomized trial of roxithromycin in non-Q wave coronary syndromes: ROXIS pilot study. Lancet1997;350: 404–7.
71.
GuptaSLeathamEWCarringtonDMendallMAKaskiJCCammAJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation1997;96: 404–7.
72.
LipGYHBeeversDG. Can we treat coronary artery disease with antibiotics? Lancet1997;350: 378–9.
73.
MartinDBursilJQuiMRBreitSNCampbellT. Alternative hypothesis for efficacy of macrolides in acute coronary syndromes. Lancet1998;351: 1858–9.
74.
GraystonJT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation1998;97: 1669–70.
